OnKure Therapeutics (OKUR) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed OnKure Therapeutics (OKUR) over the past year, gaining 268.7% versus a loss of 24.3%. Over five years, RLYB leads with a -86.3% price change compared with -96.4% for OKUR. OnKure Therapeutics is the larger company by market cap ($95.8 million vs $91.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKUR | RLYB |
|---|---|---|
| Share price | $2.37 | $17.22 |
| Market cap | $95.77M | $91.48M |
| 1-day change | +2.83% | +1.35% |
| YTD return | -20.69% | +209.58% |
| 1-year return | -24.34% | +268.71% |
| 5-year return | -96.43% | -86.32% |
| P/E ratio (TTM) | — | 2.15 |
| EPS (TTM) | $-3.04 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.38 | $17.57 |
| 52-week low | $2.13 | $3.67 |
| Distance from 52-week high | -56.04% | -2.01% |
| Analyst consensus | none | — |
| Avg. price target upside | +555.39% | — |
| Average volume | 216.96K | 21.33K |
| Shares outstanding | 40.50M | 5.31M |
| Employees | 45 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed OKUR by 293.0 percentage points over the past year.
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
OKUR vs RLYB FAQ
Which is bigger, OnKure Therapeutics or Rallybio?
OnKure Therapeutics (OKUR) is larger, with a market capitalization of $95.77M compared with $91.48M for Rallybio (RLYB).
Which stock has performed better over the past year, OKUR or RLYB?
RLYB returned +268.71% over the past 12 months, compared with -24.34% for OKUR (price return, excluding dividends). Past performance does not predict future results.
Are OnKure Therapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.